Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
about
Use of atypical antipsychotics in the elderly: a clinical reviewPharmacotherapy of schizophrenic patients: preponderance of off-label drug useCost of antipsychotic polypharmacy in the treatment of schizophrenia.Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyAntipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorTreatment of the special patient with schizophrenia.A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999.Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceLong-term antipsychotic polypharmacy: how does it start, why does it continue?Concept and Management of Treatment Resistant Schizophrenia (TRS)Anti-psychotic drug prescription pattern for schizophrenia: Observation from a general hospital psychiatry unit.Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
P2860
Q26827756-34A3EBBE-2261-4E80-9889-F2EA82B9356AQ28473574-E9BFF892-B592-41E1-B4E7-4EDE5C4D06C6Q33327172-CDD29513-105D-4E20-8F79-2C40454F1697Q33747710-1EE683CA-CE37-40C4-B7C9-FF648BA008D4Q35030003-FFA18843-13DC-40D7-BE0B-39429953D57FQ35175610-5FBD9CA2-DAF6-4A75-8EB6-ED2F0668767FQ35236370-4B7BD7DB-4445-483A-8A73-1680D9D67F9AQ35795401-B490EDF0-1172-442A-B49F-78313CF9D330Q35804079-8D7BD573-384B-4E75-AF27-BF288E297D9CQ35826319-EBC221F6-09B8-4FFD-8FF9-93A2FAFBE678Q35884276-ED73F8FD-9FA6-42DF-B939-1B0EE01D3895Q36057820-EA4BDC9B-B26E-4EE0-8809-90C449A58B26Q37029622-E3929A18-A4AA-4944-8BD3-9C672D069213Q37079008-5900E36A-43DF-4EED-B47D-20AF220E89EAQ40521264-7A961DE4-04B0-447E-829B-312EC312C35FQ41564243-D1DD6832-0D21-43A7-8B0B-E1C777BC90B0Q42835527-B6157DEB-FA53-4115-A9B0-304C8CB58936Q48276772-D285658C-E873-4A3D-9B22-01EA4369A502
P2860
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
@en
type
label
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
@en
prefLabel
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
@en
P356
P1476
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
@en
P2093
P304
P356
10.4088/JCP.V60N0701
P577
1999-07-01T00:00:00Z